作者: Bo. Eklof , Berndt Arfvidsson , Robert L. Kistner , Elna M. Masuda
DOI: 10.1016/S0889-8588(05)70146-5
关键词: Urokinase 、 Medicine 、 Femoral vein 、 Surgery 、 Thrombus 、 Tissue plasminogen activator 、 Reduction (orthopedic surgery) 、 Phlegmasia cerulea dolens 、 Venous Obstruction 、 Thrombolysis
摘要: The goals of treatment acute iliofemoral DVT should be prevention fatal PE, reduction pain and swelling the involved leg, trying to stop development phlegmasia cerulea dolens venous gangrene, disabling PTS by early removal blood clot, avoiding proximal obstruction, preserving normal, functioning valves in leg veins, preventing reflux. authors recommend an aggressive approach with rapid occluding thrombus veins extending up into iliac active patients a short history symptomatic DVT, usually less than 7 days. This is not justified chronically ill, bedridden, high-risk, or aged patients, those serious intercurrent disease limited life expectancy. In these such interventions can only indicated for limb salvage when conservative does prevent compartment syndrome gangrene. preferred means accomplishing quick CDITT. Most authors' positive experience thrombolysis based on use urokinase. Food Drug Administration (FDA) has put this drug temporary hold almost 1 year. alternative drugs (e.g., tissue plasminogen activator [tPA]) have been tested CDITT tPA FDA-approved indication. When there are contraindications failure thrombolysis, TE AVF valid alternative.